Streptococcal Group B Infection Overview

Save information for later
Sign Up

Learn About Streptococcal Group B Infection

What is the definition of Streptococcal Group B Infection?
Group B streptococcus is a blood infection (septicemia) caused by the bacterium, Streptococcus agalactiae, which affects newborn babies. The infection is categorized into two syndromes: 1) early onset (<7 days old) and 2) late onset (7-90 days old). The infection can be caused when the baby moves through the birth canal (early onset), or the baby can become infected after birth through contact with carriers of the bacteria (late onset). Both syndromes can develop into pneumonia and meningitis.
What are the symptoms of Streptococcal Group B Infection?
Symptoms of Group B streptococcal infection in the newborn can include appearing anxious or stressed, blue skin (cyanosis), breathing difficulties, fast or slow heart rate, lethargy, pale, cold skin, poor feeding, and a low or high temperature.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Streptococcal Group B Infection?
The main treatment for Group B streptococcal infection in the newborn is intravenous (IV) antibiotics. Other treatments can include breathing support, intravenous fluids, treatment of shock, correction of blood clotting abnormalities, oxygen therapy, and, in severe cases, the use of a pump to circulate blood through an artificial lung (extracorporeal membrane oxygen).
Who are the top Streptococcal Group B Infection Local Doctors?
Shabir A. Madhi
Elite in Streptococcal Group B Infection
Shabir A. Madhi
Elite in Streptococcal Group B Infection
Shabir A. Madhi
Johannesburg, GT, ZA 

Shabir Madhi practices in Johannesburg, South Africa. Madhi and is rated as an Elite expert by MediFind in the treatment of Streptococcal Group B Infection. Their top areas of expertise are Streptococcal Group B Infection, Strep Throat, Flu, and Pneumonia.

Kirsty Le Doare
Elite in Streptococcal Group B Infection
Kirsty Le Doare
Elite in Streptococcal Group B Infection
Kirsty Le Doare
St George's University Of London, 
London, ENG, GB 

Kirsty Le Doare practices in London, United Kingdom. Le Doare and is rated as an Elite expert by MediFind in the treatment of Streptococcal Group B Infection. Her top areas of expertise are Streptococcal Group B Infection, Neonatal Sepsis, Strep Throat, and Meningitis.

 
 
 
 
Learn about our expert tiers
Learn More
David M. Aronoff
Elite in Streptococcal Group B Infection
Dr. David M. Aronoff
Infectious Disease
Elite in Streptococcal Group B Infection
Dr. David M. Aronoff
Infectious Disease

University Medical Diagnostic Associates Inc

550 N University Blvd, 
Indianapolis, IN 
217-274-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

David Aronoff is an Infectious Disease provider in Indianapolis, Indiana. Dr. Aronoff and is rated as an Elite provider by MediFind in the treatment of Streptococcal Group B Infection. His top areas of expertise are Streptococcal Group B Infection, Strep Throat, Sepsis, and Pneumonia. Dr. Aronoff is currently accepting new patients.

View All Doctors
What are the latest Streptococcal Group B Infection Clinical Trials?
A Phase I/II, Observer-Blind, Randomized, Placebo-Controlled, Dose-Selection Study to Assess the Safety, Tolerability, and Immunogenicity of Hexavalent Group B Streptococcus Conjugate Vaccine Manufactured by Inventprise, Inc., in Healthy, Non-Pregnant, Adult Women of Childbearing Age (WOCBA) in the US and South Africa.
A Phase I/II, Observer-Blind, Randomized, Placebo-Controlled, Dose-Selection Study to Assess the Safety, Tolerability, and Immunogenicity of Hexavalent Group B Streptococcus Conjugate Vaccine Manufactured by Inventprise, Inc., in Healthy, Non-Pregnant, Adult Women of Childbearing Age (WOCBA) in the US and South Africa.
Enrollment Status: Recruiting
Publish Date: January 17, 2025
Intervention Type: Biological
Study Phase: Phase 1/Phase 2

Summary: To assess the safety and tolerability of IVT GBS-06 vaccine administered as a single-dose regimen, at three dosage levels in healthy, non-pregnant, adult women of childbearing age (WOCBA).

Match to trials
Find the right clinical trials for you in under a minute
Get started
Development of a Serocorrelate of Protection Against Invasive Group B Streptococcus Disease
Development of a Serocorrelate of Protection Against Invasive Group B Streptococcus Disease
Enrollment Status: Recruiting
Publish Date: November 22, 2023
Intervention Type: Other

Summary: A multicentre study to provide evidence that the relationship between an immune marker value (anti-GBS IgG concentration) and the probability of invasive GBS (iGBS) disease in infants less than 90 days of age is sufficiently strong that a vaccine able to induce an immune response will lead to a meaningful decrease in the probability of iGBS disease.

View All Clinical Trials